Pharmaceutical Product Development Reaches New 52-Week High (PPDI)

NEW YORK ( TheStreet) -- Pharmaceutical Product Development (Nasdaq: PPDI) hit a new 52-week high Monday as it is currently trading at $33.12, above its previous 52-week high of $33.09 with 3.3 million shares traded as of four p.m. ET. Average volume has been 2.9 million shares over the past 30 days.

Pharmaceutical Product Development has a market cap of $3.7 billion and is part of the health care sector and health services industry. Shares are up 21.8% year to date as of the close of trading on Friday.

Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Clinical Development Services and Laboratory Services. The company has a P/E ratio of 51.5, above the average health services industry P/E ratio of 22.5 and above the S&P 500 P/E ratio of 17.7.
  • Practice your PPDI trading strategies and win cash in our stock game.

TheStreet Ratings rates Pharmaceutical Product Development as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pharmaceutical Product Development Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Soars on Signs of Progress in U.S.-China Trade Discussions

Dow Soars on Signs of Progress in U.S.-China Trade Discussions

Is It Safe?

Is It Safe?

Tax Loss Selling Recovery Candidates, Part 2

Tax Loss Selling Recovery Candidates, Part 2

Microsoft, Amazon, Apple Are Top Holdings of U.S. Hedge Funds

Microsoft, Amazon, Apple Are Top Holdings of U.S. Hedge Funds

Workday Has Been Working Higher on the Charts - More Gains to Come

Workday Has Been Working Higher on the Charts - More Gains to Come